During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...
Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal ...
Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment for patients with low-grade, intermediate-risk non–muscle-invasive bladder ...
For Heart Health Month, Amy Ahnert, MD, discussed the link between cardiovascular disease and breast cancer.
Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with myelofibrosis, ...
The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...
Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, ...
Marwan G. Fakih, MD, provides an overview of the study design, rationale, and findings from a phase 2 trial of balstilimab with botensilimab for the treatment of patients with microsatellite stable ...
Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...
Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...
David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...